伏立康唑治疗儿童侵袭性肺部真菌感染疗效观察

Efficacy of Voriconazole in the Treatment of Invasive Pulmonary Fungal Infection in Children

目的:探讨伏立康唑治疗儿童侵袭性肺部真菌感染(IPFI)的临床效果及安全性。方法:收集我院儿科呼吸病房2018年2月至2019年1月收治的IPFI患儿88例,采用随机数表法分为伏立康唑组和米卡芬净组各44例,分别选用伏立康唑和米卡芬净进行治疗,疗程均为4~6周,比较两组患儿的临床疗效与不良反应发生率。结果:伏立康唑组总有效率93.18%,高于米卡芬净组的77.27%;伏立康唑组临床症状消退时间、痰培养转阴时间、影像学病灶吸收时间均短于米卡芬净组(P均<0.05),两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:伏立康唑治疗儿童IPFI的临床疗效优于米卡芬净,且用药安全,可作为儿童IPFI的有效抗真菌药物在临床上推广应用。

Objective:To probe into the clinical efficacy and safety of voriconazole in the treatment of invasive pulmonary fungal infection(IPFI)in children.Methods:Totally 88 children with IPFI admitted into our hospital from Feb.2018 to Jan.2019 were extracted to be divided into the voriconazole group and the micafungin group via the random number table,with 44 cases in each group,voriconazole and micafungin were retrospectively given for treatment of 4 to 6 weeks.Clinical efficacy and incidence of adverse drug reactions were compared between two groups.Results:The total effective rate of the voriconazole group was 93.18%,higher than 77.27%of the micafungin group.The disappearance time of clinical symptoms,the conversion time of sputum culture,and the absorption time of imaging lesions in the voriconazole group were shorter than those in the micafungin group(P<0.05).There was no significant difference in the incidence of adverse drug reactions between two groups(P>0.05).Conclusion:The clinical efficacy of voriconazole in the treatment of children with IPFI is better than that of micafungin,and it is safe to be used as the effective anti-fungal drug for children with IPFI in clinical application.